Tiragolumab
- Generic Name
- Tiragolumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
- Associated Conditions
- -
- Associated Therapies
- -
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
- Conditions
- Recurrent Rhabdoid TumorRefractory Epithelioid SarcomaRefractory Kidney Medullary CarcinomaRefractory Malignant Solid NeoplasmEpithelioid SarcomaMalignant Solid NeoplasmKidney Medullary CarcinomaRecurrent Epithelioid SarcomaRecurrent Malignant Solid NeoplasmRefractory Atypical Teratoid/Rhabdoid Tumor
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT05286801
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 92
- Registration Number
- NCT05259319
- Locations
- 🇫🇷
Centre Georges François Leclerc (CGFL), Dijon, Bourgogne, France
An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05251948
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou City, China
🇨🇳Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou City, China
🇨🇳The General Hospital of People?s Liberation Army (301 Hospital), Beijing City, China
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
- Conditions
- Interventions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT05116202
- Locations
- 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
🇺🇸The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States
🇮🇹Ospedale S.Maria della Misericordia, Perugia, Umbria, Italy
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT05060003
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT05009069
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, China
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 42
- Registration Number
- NCT04958811
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
- Conditions
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT04933227
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Beijing Cancer Hospital, Beijing, China
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT04929223
- Locations
- 🇺🇸
cCare, Encinitas, California, United States
🇺🇸Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT04832854
- Locations
- 🇨ðŸ‡
Kantonsspital Winterthur; Medizinische Onkologie, Winterthur, Switzerland
🇨ðŸ‡UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland
🇦🇺Cabrini Hospital Malvern, Malvern, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.